Atul Dandekar Sells 7,500 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $27.58, for a total value of $206,850.00. Following the completion of the sale, the insider owned 26,250 shares in the company, valued at approximately $723,975. This represents a 22.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.34, for a total transaction of $205,050.00.
• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $28.02, for a total transaction of $210,150.00.

Maze Therapeutics Trading Down 0.2%

NASDAQ MAZE opened at $26.53 on Wednesday. Maze Therapeutics, Inc. has a 1 year low of $14.16 and a 1 year high of $53.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The company has a market capitalization of $1.47 billion, a PE ratio of -10.53 and a beta of 2.17. The company has a fifty day moving average of $28.76 and a 200 day moving average of $31.49.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting analysts’ consensus estimates of ($0.76). Research analysts forecast that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MAZE. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. BTIG Research reissued a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, August 12th. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $66.00.

Institutional Trading of Maze Therapeutics

Several institutional investors have recently bought and sold shares of MAZE. Royal Bank of Canada raised its stake in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after buying an additional 363 shares during the period. Ameritas Investment Partners Inc. grew its stake in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in Maze Therapeutics in the 4th quarter worth $43,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Maze Therapeutics during the second quarter worth $48,000. Finally, Russell Investments Group Ltd. raised its position in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.